Hepatitis B

The hepatitis B focuses on a viral infection that primarily targets the liver, leading to both acute and chronic disease outcomes with significant global health impact. This session explores how the hepatitis B virus (HBV) spreads, establishes persistent infection, and contributes to complications such as liver cirrhosis and hepatocellular carcinoma. At the Infectious Diseases Conference, experts will examine the evolving epidemiology of hepatitis B and the challenges associated with long-term disease control.

Hepatitis B is transmitted through exposure to infected blood and bodily fluids, including perinatal transmission, unsafe injections, and unprotected sexual contact. The infection can remain asymptomatic for long periods, allowing silent progression to chronic liver disease. Early detection through screening and serological testing is essential for preventing complications and reducing transmission risk.

Clinical management involves antiviral therapy to suppress viral replication, along with regular monitoring of liver function and disease progression. Vaccination remains one of the most effective preventive measures, significantly reducing infection rates in populations with high immunization coverage. However, disparities in vaccine access and healthcare infrastructure continue to influence global disease distribution.

A clinical tracking construct, HBV Disease, is applied in patient management systems to observe long-term disease progression patterns, treatment response variability, and population-level infection trends without focusing on descriptive interpretation of the framework.

Efforts to control hepatitis B increasingly rely on integrated strategies that combine vaccination programs, screening initiatives, and sustained clinical care models to reduce transmission and improve patient outcomes globally.